- 現金殖利率: 2.81%、總殖利率: 2.81%、5年平均現金配發率: 24.19%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
2023 (10) | -0.13 | 0 | 0.70 | -72.0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2022 (9) | 3.10 | -40.5 | 2.50 | 19.05 | 0.00 | 0 | 80.65 | 100.08 | 0.00 | 0 | 80.65 | 100.08 |
2021 (8) | 5.21 | 0 | 2.10 | 950.0 | 0.00 | 0 | 40.31 | 0 | 0.00 | 0 | 40.31 | 0 |
2020 (7) | -0.68 | 0 | 0.20 | 0.0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2019 (6) | -0.34 | 0 | 0.20 | -52.38 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
2018 (5) | 0.33 | -8.33 | 0.42 | -12.5 | 0.00 | 0 | 127.27 | -4.55 | 0.00 | 0 | 127.27 | -4.55 |
2017 (4) | 0.36 | -69.75 | 0.48 | -52.0 | 0.00 | 0 | 133.33 | 58.67 | 0.00 | 0 | 133.33 | 58.67 |
2016 (3) | 1.19 | -3.25 | 1.00 | 1.01 | 0.00 | 0 | 84.03 | 4.41 | 0.00 | 0 | 84.03 | 4.41 |
EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
---|---|---|---|---|---|---|---|---|---|
24Q3 (20) | 0.02 | -92.86 | -77.78 | 0.06 | -70.0 | 140.0 | 0.74 | 4.23 | 516.67 |
24Q2 (19) | 0.28 | -34.88 | 1300.0 | 0.20 | 0.0 | 242.86 | 0.71 | 65.12 | 2266.67 |
24Q1 (18) | 0.43 | 272.0 | 4200.0 | 0.20 | 33.33 | 53.85 | 0.43 | 430.77 | 4200.0 |
23Q4 (17) | -0.25 | -377.78 | 53.7 | 0.15 | 200.0 | -60.53 | -0.13 | -208.33 | -104.09 |
23Q3 (16) | 0.09 | 350.0 | -90.72 | -0.15 | -7.14 | -134.88 | 0.12 | 300.0 | -96.77 |
23Q2 (15) | 0.02 | 100.0 | -98.96 | -0.14 | -207.69 | -109.33 | 0.03 | 200.0 | -98.91 |
23Q1 (14) | 0.01 | 101.85 | -98.78 | 0.13 | -65.79 | -79.37 | 0.01 | -99.69 | -98.78 |
22Q4 (13) | -0.54 | -155.67 | -114.21 | 0.38 | -11.63 | 222.58 | 3.18 | -14.52 | -39.77 |
22Q3 (12) | 0.97 | -49.74 | 5.43 | 0.43 | -71.33 | -45.57 | 3.72 | 34.78 | 151.35 |
22Q2 (11) | 1.93 | 135.37 | 244.64 | 1.50 | 138.1 | 233.33 | 2.76 | 236.59 | 392.86 |
22Q1 (10) | 0.82 | -78.42 | 0 | 0.63 | 303.23 | 472.73 | 0.82 | -84.47 | 0 |
21Q4 (9) | 3.80 | 313.04 | 1004.76 | -0.31 | -139.24 | -3000.0 | 5.28 | 256.76 | 876.47 |
21Q3 (8) | 0.92 | 64.29 | 355.56 | 0.79 | 75.56 | 758.33 | 1.48 | 164.29 | 648.15 |
21Q2 (7) | 0.56 | 0 | 600.0 | 0.45 | 309.09 | 87.5 | 0.56 | 0 | 460.0 |
21Q1 (6) | 0.00 | 100.0 | -100.0 | 0.11 | 1200.0 | 22.22 | 0.00 | 100.0 | -100.0 |
20Q4 (5) | -0.42 | -16.67 | -55.56 | -0.01 | 91.67 | -107.69 | -0.68 | -151.85 | -100.0 |
20Q3 (4) | -0.36 | -550.0 | 0.0 | -0.12 | -150.0 | 0.0 | -0.27 | -370.0 | 0.0 |
20Q2 (3) | 0.08 | 300.0 | 0.0 | 0.24 | 166.67 | 0.0 | 0.10 | 400.0 | 0.0 |
20Q1 (2) | 0.02 | 107.41 | 0.0 | 0.09 | -30.77 | 0.0 | 0.02 | 105.88 | 0.0 |
19Q4 (1) | -0.27 | 0.0 | 0.0 | 0.13 | 0.0 | 0.0 | -0.34 | 0.0 | 0.0 |
年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
---|---|---|---|---|---|---|---|---|---|---|
2024/10 | 1.75 | -5.32 | -6.93 | 18.27 | 1.96 | 5.47 | N/A | - | ||
2024/9 | 1.85 | -1.17 | -6.24 | 16.52 | 3.01 | 5.66 | 0.68 | - | ||
2024/8 | 1.87 | -3.62 | 0.85 | 14.67 | 4.3 | 5.64 | 0.68 | - | ||
2024/7 | 1.94 | 6.25 | 9.73 | 12.8 | 4.83 | 5.65 | 0.68 | - | ||
2024/6 | 1.83 | -3.06 | 3.75 | 10.86 | 4.0 | 5.56 | 0.72 | - | ||
2024/5 | 1.88 | 2.03 | 4.65 | 9.03 | 4.05 | 5.53 | 0.73 | - | ||
2024/4 | 1.85 | 2.45 | 7.43 | 7.15 | 3.89 | 5.26 | 0.76 | - | ||
2024/3 | 1.8 | 12.01 | -6.48 | 5.3 | 2.71 | 5.3 | 0.75 | - | ||
2024/2 | 1.61 | -14.94 | 3.06 | 3.5 | 8.19 | 5.14 | 0.77 | - | ||
2024/1 | 1.89 | 15.48 | 12.97 | 1.89 | 12.97 | 5.33 | 0.74 | - | ||
2023/12 | 1.64 | -8.89 | -22.59 | 21.35 | -36.42 | 5.32 | 0.71 | - | ||
2023/11 | 1.8 | -4.36 | -14.36 | 19.71 | -37.35 | 5.65 | 0.66 | - | ||
2023/10 | 1.88 | -4.62 | -5.11 | 17.91 | -38.99 | 5.7 | 0.66 | - | ||
2023/9 | 1.97 | 6.3 | 1.73 | 16.03 | -41.44 | 5.59 | 0.6 | - | ||
2023/8 | 1.85 | 4.85 | -14.71 | 14.06 | -44.73 | 5.38 | 0.62 | - | ||
2023/7 | 1.77 | 0.46 | -46.31 | 12.21 | -47.53 | 5.33 | 0.62 | - | ||
2023/6 | 1.76 | -2.22 | -65.38 | 10.44 | -47.73 | 5.28 | 0.87 | 去年營收因子公司出售快篩試劑,致使本月營收較去年同期減少達50%以上 | ||
2023/5 | 1.8 | 4.74 | -65.09 | 8.68 | -41.71 | 5.45 | 0.84 | 去年營收因子公司出售快篩試劑,致使本月營收較去年同期減少達50%以上 | ||
2023/4 | 1.72 | -10.82 | -32.9 | 6.88 | -29.33 | 5.21 | 0.88 | - | ||
2023/3 | 1.93 | 23.44 | -22.56 | 5.16 | -28.05 | 5.16 | 1.04 | - | ||
2023/2 | 1.56 | -6.75 | -29.68 | 3.24 | -30.97 | 5.35 | 1.0 | - | ||
2023/1 | 1.67 | -20.87 | -32.13 | 1.67 | -32.13 | 5.89 | 0.91 | - | ||
2022/12 | 2.12 | 0.79 | -14.01 | 33.58 | 14.58 | 6.2 | 0.88 | - | ||
2022/11 | 2.1 | 5.96 | -19.84 | 31.46 | 17.2 | 6.02 | 0.91 | - | ||
2022/10 | 1.98 | 2.25 | -25.28 | 29.36 | 21.21 | 6.09 | 0.9 | - | ||
2022/9 | 1.94 | -10.88 | -30.92 | 27.38 | 26.92 | 7.4 | 0.89 | - | ||
2022/8 | 2.17 | -33.99 | -17.28 | 25.45 | 35.56 | 10.55 | 0.63 | - | ||
2022/7 | 3.29 | -35.22 | 20.12 | 23.27 | 44.17 | 13.53 | 0.49 | - | ||
2022/6 | 5.08 | -1.39 | 109.69 | 19.98 | 49.09 | 12.8 | 0.59 | 因嘉碩生醫出售快篩試劑,致使本月營收較去年同期增加達50%以上 | ||
2022/5 | 5.16 | 101.32 | 125.9 | 14.89 | 35.7 | 10.21 | 0.74 | 本月營收因子公司出售快篩試劑,致使本月營收較去年同期增加達50%以上 | ||
2022/4 | 2.56 | 2.92 | 11.5 | 9.74 | 12.02 | 7.27 | 1.05 | - | ||
2022/3 | 2.49 | 12.08 | 4.13 | 7.18 | 12.2 | 7.18 | 0.72 | - | ||
2022/2 | 2.22 | -10.0 | 24.43 | 4.69 | 17.02 | 7.15 | 0.72 | - | ||
2022/1 | 2.47 | 0.25 | 11.06 | 2.47 | 11.06 | 7.55 | 0.68 | - | ||
2021/12 | 2.46 | -6.04 | 23.37 | 29.31 | 37.18 | 7.73 | 0.64 | - | ||
2021/11 | 2.62 | -1.22 | 39.04 | 26.84 | 38.6 | 8.07 | 0.61 | - | ||
2021/10 | 2.65 | -5.46 | 50.07 | 24.23 | 38.56 | 8.08 | 0.61 | 本月營收因出貨量增加及調整營運策略,致使本月營收較去年同期增加達50%以上 | ||
2021/9 | 2.8 | 6.7 | 60.17 | 21.57 | 37.26 | 8.17 | 0.59 | 本月營收因出貨量增加及調整營運策略,致使本月營收較去年同期增加達50%以上 | ||
2021/8 | 2.63 | -4.13 | 62.3 | 18.77 | 34.39 | 7.79 | 0.62 | 本月營收因出貨量增加及調整營運策略,致使本月營收較去年同期增加達50%以上 | ||
2021/7 | 2.74 | 13.07 | 52.35 | 16.14 | 30.73 | 7.45 | 0.64 | 本月營收因出貨量增加及調整營運策略,致使本月營收較去年同期增加達50%以上。 | ||
2021/6 | 2.42 | 6.22 | 41.44 | 13.4 | 27.04 | 7.0 | 0.57 | - | ||
2021/5 | 2.28 | -0.63 | 29.17 | 10.98 | 24.24 | 6.97 | 0.57 | - | ||
2021/4 | 2.3 | -3.87 | 14.25 | 8.69 | 23.01 | 6.47 | 0.62 | - | ||
2021/3 | 2.39 | 33.94 | 24.33 | 6.4 | 26.5 | 6.4 | 0.6 | - | ||
2021/2 | 1.78 | -19.67 | 8.94 | 4.01 | 27.82 | 6.0 | 0.64 | - | ||
2021/1 | 2.22 | 11.36 | 48.5 | 2.22 | 48.5 | 6.1 | 0.63 | - | ||
2020/12 | 1.99 | 5.89 | 9.29 | 21.36 | 5.44 | 5.64 | 0.6 | - | ||
2020/11 | 1.88 | 6.61 | -0.38 | 19.37 | 5.06 | 5.4 | 0.63 | - | ||
2020/10 | 1.77 | 0.9 | -13.19 | 17.48 | 5.68 | 5.14 | 0.66 | - | ||
2020/9 | 1.75 | 8.12 | 7.16 | 15.72 | 8.33 | 5.17 | 0.81 | - | ||
2020/8 | 1.62 | -10.01 | -16.72 | 13.97 | 8.48 | 5.13 | 0.82 | - | ||
2020/7 | 1.8 | 4.97 | -4.37 | 12.35 | 12.96 | 5.28 | 0.8 | - | ||
2020/6 | 1.71 | -2.98 | 0.74 | 10.55 | 16.57 | 5.49 | 0.8 | - | ||
2020/5 | 1.77 | -12.1 | 2.51 | 8.83 | 20.23 | 5.7 | 0.77 | - | ||
2020/4 | 2.01 | 4.59 | 27.57 | 7.07 | 25.67 | 5.57 | 0.79 | - | ||
2020/3 | 1.92 | 17.36 | 29.75 | 5.06 | 24.93 | 5.06 | 0.78 | - | ||
2020/2 | 1.64 | 9.49 | 44.01 | 3.13 | 22.14 | 4.96 | 0.79 | - | ||
2020/1 | 1.5 | -18.04 | 4.73 | 1.5 | 4.73 | 5.21 | 0.76 | - | ||
2019/12 | 1.82 | -3.48 | 41.88 | 20.26 | 9.44 | 0.0 | N/A | - | ||
2019/11 | 1.89 | -7.09 | 35.38 | 18.43 | 7.02 | 0.0 | N/A | - |